LOS ANGELES, Oct. 29, 2014 /PRNewswire/ -- ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is committed to pursuing out-licensing partnerships in 2015.
ViaDerma has developed an innovative, patent-pending dual carrier transdermal delivery method, which allows for rapid mass transfer of pharmaceutical active ingredients to penetrate the skin and into the body to provide immediate localized therapy. The transdermal delivery method also overcomes microbial drug resistances, which the Company believes will prolong the viability of antibiotics for years to come. The company has potential to pair this technology with a wide variety of active ingredients to develop new antimicrobial drugs with pharmaceutical companies that license from ViaDerma.
"This delivery system is unique in the market. It was originally developed to treat diabetes foot wounds, but the technology worked so well that physicians came to us and asked if we could use it for other indications," said Dr. Christopher Otiko, CEO of ViaDerma. "We are excited to pursue partnerships and license our technology to combine with existing medications."
In the coming months, ViaDerma will be dedicated to research and development, growing market awareness and actively seeking licensing opportunities in order to expand business development and distribution for this technology in 2015. The Company believes its technology may be applicable in many fields including: sports nutrition supplements, cosmetics, first-aid products, wound care and various skin diseases such as: acne, eczema and psoriasis.
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.
Contact
Dr. Christopher Otiko
Chief Executive Officer
ViaDerma, Inc.
info@viadermalicensing.com
818-836-2475
Kristi Hofacker
Director of Interactive Marketing & Media
The Brewer Group
kristi.hofacker@thebrewergroup.com
Forward Looking Statements
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in our filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ViaDerma, Inc.